Talha Jalal/LinkedIn
Jul 26, 2025, 20:00
EU’s Medicine Strategy is Focused on Supply Chains, But Overlooks the Deeper Risk
Lung Cancer Europe shared on LinkedIn:
“This is a really important piece by Talha Jalal – one of Lung Cancer Europe’s Policy Advisors (currently on sabbatical).
He argues that the EU’s medicine strategy is focused on supply chains, but overlooks the deeper risk: drugs becoming ineffective because of underinvestment in trials, antibiotics, and innovation.
For people with lung cancer, it means fewer options and less time.
The Critical Medicines Act won’t fix that on its own.
Published via European University Institute.”
More posts featuring Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 8, 2025, 02:00
Sep 7, 2025, 23:56
Sep 7, 2025, 23:47
Sep 7, 2025, 16:47
Sep 7, 2025, 16:30
Sep 7, 2025, 16:25